Progenity, Inc., a privately held biotechnology company, today announced the expansion of its board of directors with four new directors to support the company as it executes its plans to develop and commercialize precision medicine solutions across its genomic/epigenomic, proteomic, and microbiomic platforms. Progenity is pleased to welcome Jeffrey D. Alter, John T. Bigalke, Samuel R. Nussbaum, MD, and Lynne Powell to its board of directors.
"Our pipeline of diagnostic and therapeutic applications under development continues to grow with innovative solutions aimed at transforming prenatal, perinatal, and gastrointestinal healthcare," said Harry Stylli, PhD, CEO, Chairman of the Board, and Founder of Progenity. "These accomplished individuals, with their combined experience in finance, risk management, managed care, business and clinical strategy, and policy will be a valuable resource for Progenity in advancing future products into clinical practice and driving its mission to make healthcare more precise and personal."
Progenity's pipeline of precision medicine solutions under development includes novel products for noninvasive prenatal screening for monogenic diseases, and assays related to preeclampsia, preterm birth, oncology, and others. Progenity also aims to transform gastrointestinal (GI) based healthcare and improve clinical outcomes through development of ingestible molecular diagnostics and therapeutic products for GI disorders such as inflammatory bowel disease (IBD).
Jeffrey D. Alter hasextensive experience in health plan management, business strategy, and mergers and acquisitions. Mr. Alter is currently President of Arcturus One Consulting and was formerly CEO of UnitedHealthcare's Commercial Group. During Mr. Alter's 14 years with UnitedHealthcare, he led its largest business unit, generating $51 billion in revenue. He was instrumental in instituting strategic initiatives that significantly improved organic growth, client relationships and retention rates. He also developed strategies that expanded the geographic footprint and diversification of the business portfolio, acquired new businesses, and improved product margin stability. Mr. Alter also successfully led UnitedHealthcare's implementation of the Affordable Care Act. Prior to this, he served as Senior Vice President of Strategic Financial Planning for Oxford Health Plans, served as Vice President of Finance, Underwriting and Operations at Vytra Health Plans, and spent ten years in finance and operations roles for Grumman Aerospace Corporation and Harris Corporation. Mr. Alter serves on several boards,including the Long Island Association, the Board of Governors of St. John's University, and CityMD. He received a BS in marketing and an MBA in finance from St. John's University.
John T. Bigalke is a seasoned financial expert and a board member and advisor to healthcare and life science companies. He is a Board Leadership Fellow with the National Association of Corporate Directors. Mr. Bigalke founded and is currently CEO of Second Half Healthcare Advisors, where he consults on business strategy for companies competing in the rapidly changing health care environment. His previous roles were U.S. National Industry Leader and Senior Partner, Global Health Care and Life Sciences at Deloitte LLP, where he led the growth to become the leading professional services firm serving the industry. Mr. Bigalke led a wide range of engagements over 18 years at Deloitte and 40 years in the industry, providing audit, litigation support, mergers and acquisitions, regulatory advisory and strategic planning services. He also served as the National Director of Public Policy, leading the development of Deloitte's public policy strategy. Mr. Bigalke serves as chairman of the Advisory Board at VaxCare Corporation and is a member of the Board of Directors at Advent (formerly Adventist) Health Systems. He is a Senior Advisor to Concord Management Services LLC. He previously served on the Board of Directors of Deloitte LLP and the Healthcare Financial Management Association, among others. He received a BS in Financial Management from Clemson University and is a licensed Certified Public Accountant.
Samuel R. Nussbaum, MD, is a clinical leader, academic physician, and policy advisor to top healthcare companies. Dr. Nussbaum has expertise in technology ...
(All Rights Reserved)